Association of N-terminal pro C-type natriuretic peptide and endothelin-1 levels with the risk of cardiovascular complications in arterial hypertension six months after COVID-19

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. Despite the significant decline in the prevalence of COVID-19 around the world, the consequences of the pandemic on the health and quality of life of patients according to the data from clinical studies will remain a leading public health issue for a long time.

Objective. Dynamic evaluation and analysis of the N-terminal pro C-type natriuretic peptide (NUPC) and endothelin-1 (ET-1) levels in patients six months after COVID-19 against the background of arterial hypertension (AH), depending on the stratification of cardiovascular risk in AH.

Methods. 45 hypertensive patients with confirmed diagnosis of coronavirus infection COVID-19 (virus identified) who were treated in an infectious diseases hospital were examined. Determination of the NUPC and ET-1 levels in blood serum samples was carried out using the enzyme immunoassay method. Biomarker levels were determined twice – on the first day of admission to the hospital and six months after discharge. Cardiovascular risk in AH was also assessed twice – on the first day of admission to the hospital and six months after discharge.

Results. Analysis of the NUPC and ET-1 levels on hospital admission between patients with moderate risk (risk 2) and high risk (risk 3) did not show statistically significant differences (P=0.487, P=0.821, respectively). Six months after COVID-19, in hypertensive patients with very high risk (risk 4), the levels of both ET-1 and NUPC were statistically significantly higher than in patients with high risk (risk 3) (P=0.012 and P<0.001, respectively). An increase in cardiovascular risk in AH six months after discharge from hospital was observed in 15 (33.3%) patients, and in 30 (66.7%) patients, cardiovascular risk in AH remained the same. In hypertensive patients who experienced an increase in cardiovascular risk six months after discharge from hospital for COVID-19, the levels of both ET-1 and NUPC were statistically significantly higher compared with patients who cardiovascular risk in AH did not change (P=0.01 and P<0.001, respectively).

Conclusion. According to the results of the study, it was found that the highest levels of both ET-1 and NUPC six months after discharge from the hospital were in patients with a very high risk (risk 4) and in patients who had an increase in cardiovascular risk in AH.

Толық мәтін

Рұқсат жабық

Авторлар туралы

A. Shuvalova

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID iD: 0009-0003-1912-7300
Ресей, Astrakhan

T. Prokofieva

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID iD: 0000-0002-3260-2677
Ресей, Astrakhan

O. Polunina

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Email: gilti2@yandex.ru
ORCID iD: 0000-0001-8299-6582
Ресей, Astrakhan

Ekaterina Polunina

Astrakhan State Medical University, Department of Internal Medicine, Faculty of Pediatrics

Хат алмасуға жауапты Автор.
Email: gilti2@yandex.ru
ORCID iD: 0000-0002-3679-432X

Dr. Sci. (Med.), Professor of the Department of Internal Medicine Faculty of Pediatrics

Ресей, Astrakhan

Әдебиет тізімі

  1. Huang L., Li X., Gu X., et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863–76. doi: 10.1016/S2213-2600(22)00126-6.
  2. Ordinola Navarro A., Cervantes-Bojalil J., Cobos Quevedo O.J., et al. Decreased quality of life and spirometric alterations even after mild-moderate COVID-19. Respir Med. 2021;181:106391. doi: 10.1016/j.rmed.2021.106391.
  3. Чичкова В.В., Шаповалова М.А., Чичкова М.А. и др. Организация амбулаторной помощи пациентам с сахарным диабетом в условиях пандемии COVID-19 с применением телемедицинских технологий. Сахарный диабет. 2023;26(4):334–42. [Chichkova V.V., Shapovalova M.A., Chichkova M.A., et al. Organization of outpatient care for patients with diabetes mellitus in the context of the COVID-19 pandemic using telemedicine technologies. Diab Mellit. 2023;26(4):334–42. (In Russ.)]. doi: 10.14341/DM13019.
  4. Канорский С.Г. Постковидный синдром: распространенность и патогенез органных поражений, направления коррекции. Систематический обзор. Кубанский научный медицинский вестник. 2021;28(6):90–116. [Kanorskii S.G. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Nauch Med Vestn. 2021;28(6):90–116. (In Russ.)]. doi: 10.25207/1608-6228-2021-28-6-90-116.
  5. Бунова С.С., Охотникова П.И., Скирденко Ю.П. и др. COVID-19 и сердечно-сосудистая коморбидность: поиск новых подходов к снижению смертности. Кардиоваскулярная терапия и профилактика. 2021;20(4):2953. [Bunova S.S., Okhotnikova P.I., Skirdenko Yu.P., et al. COVID-19 and cardiovascular comorbidity: novel approaches to reduce mortality. Cardiovasc Ther Prevent. 2021;20(4):2953. (In Russ.)]. doi: 10.15829/1728- 8800-2021-2953.
  6. Munblit D., Nicholson T., Akrami A., et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir Med. 2022;10(7):715–24. doi: 10.1016/S2213-2600(22)00169-2.
  7. Muhamad S.A., Ugusman A., Kumar J., et al. COVID-19 and hypertension: The what, the why and the how. Front Physiol. 2021;12:665064. doi: 10.3389/fphys.2021.665064.
  8. Shrestha D.B., Budhathoki P., Raut, S., et al. New-Onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021;10:275–87. doi: 10.5501/wjv.v10.i5.275.
  9. Daugherty S.E., Guo Y., Heath K., et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. 2021;373:n1098. doi: 10.1136/bmj.n1098.
  10. Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–59. doi: 10.1001/jama.2020.6775.
  11. Чазова И.Е., Блинова Н.В., Невзорова В.А. и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и COVID-19. Системные гипертензии. 2020;17(3): 35–41. [Chazova I.E., Blinova N.V., Nevzorova V.A., et al. Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Syst Hypertens. 2020;17(3):35–41. (In Russ.)]. doi: 10.26442/2075082X.2020.3.200362.
  12. Елфимов Д.А., Елфимова И.В., Хамитова И.Р. и др. Некоторые особенности течения артериальной гипертонии у пациентов, перенесших новую коронавирусную инфекцию (COVID-19). Медицинская наука и образование Урала. 2021;2:75–9. [Elfimov D.A., Elfimova I.V., Khamitova I.R., et al. Some features of the course of arterial hypertension in patients undergoing a new coronavirus infection (COVID-19). Med Sci Educat Urals. 2021;2:75–9. (In Russ.)]. doi: 10.36361/1814-8999-2021-22-2-75-79.
  13. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3.
  14. Gallo G., Calvez V., Savoia C. Hypertension and COVID-19: Current Evidence and Perspectives. High Blood Press. Cardiovasc Prev. 2022;29(2):115–23. doi: 10.1007/s40292-022-00506-9.
  15. Uysal B., Akca T., Akacı O., et al. The Prevalence of Post-COVID-19 Hypertension in Children. Clin Pediatr (Phila). 2022;61(7):453–60. doi: 10.1177/00099228221085346.
  16. Chioh F.W., Fong S.W., Young B.E., et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. eLife. 2021;10:e64909. doi: 10.7554/eLife.64909.
  17. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3):e14726. doi: 10.14814/phy2.14726.
  18. Яровая Д.В., Башкина О.А., Красилова Е.В. Влияние коронавирусной инфекции на маркеры эндотелиальной дисфункции у детей при патологии почек. Человек и его здоровье. 2023;26(1):4–8. [Yarovaya D.V., Bashkina O.A., Krasilova E.V. Effects of coronavirus infection on markers of endothelial dysfunction in children with renal pathology. Hum Their Health. 2023;26(1):4–8 (In Russ.)]. doi: 10.21626/vestnik/2023-1/01.
  19. Голивец Т.П., Дубоносова Д.Г., Осипова О.А. и др. Эффекты эндотелина-1 в развитии и прогрессировании метаболического синдрома и других социально значимых неинфекционных заболеваний (Обзор литературы). Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2017;19(268):5–19. [Golivets T.P., Dubonosova D.G., Osipova О.А., et al. The effects of endothelin 1 in the development and progression of metabolic syndrome and socially significant non-communicable diseases (review of literature). Med Sci Educat Sci Bull Belgorod State Univer. Series: Medicine. Pharmacy. 2017;19(268):5–19. (In Russ.)].
  20. Idris-Khodja N., Ouerd S., Mian M.O.R., et al. Endothelin-1 Overexpression Exaggerates Diabetes-Induced Endothelial Dysfunction by Altering Oxidative Stress. Am J Hypertens. 2016;29(11):1245–51. doi: 10.1093/ajh/hpw078.
  21. Moyes A.J., Hobbs A.J. C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci. 2019;8;20(9):2281. doi: 10.3390/ijms20092281.
  22. Воронина Л.П. Генетические, биохимические и функциональные маркеры состояния вазорегулярующей функции эндотелия. Сибирский медицинский журнал (Иркутск). 2011;102(3):29–31. [Voronina L.P. Genetic, biochemical and functional markers of condition of vasoregulating function of endothelium. Sibir Med J (Irkutsk). 2011;102(3):29–31. (In Russ.)].
  23. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Министерства здравоохранения Российской Федерации (версии 13–14). [Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Ministry of Health of the Russian Federation (versions 13–14). (In Russ.)]. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf
  24. Клинические рекомендации «Артериальная гипертензия у взрослых», год утверждения 2020. [Clinical guidelines “Arterial hypertension in adults”, year of approval 2020. (In Russ.)]. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  25. Наследов А. SPSS 19: профессиональный статистический анализ данных. СПб., 2011. 400 с. [Nasledov A. SPSS 19: professional statistical data analysis. 2011. 400 р. (In Russ.)].
  26. Willems L.H., Nagy M., Ten Cate H., et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb Res. 2022;209:106–14. doi: 10.1016/j.thromres.2021.11.027.
  27. Abraham G.R., Kuc R.E., Althage M., et al. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J Mol Cell Cardiol. 2022;167:92–6. doi: 10.1016/j.yjmcc.2022.03.007.
  28. Bojti I., Przewosnik A.S., Luxenburger H., et al. Decreased level of serum NT-proCNP associates with disease severity in COVID-19. Respir Res. 2023;24(1):174. doi: 10.1186/s12931-023-02469-4.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2024

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>